Abstract
Several lines of evidence suggest a pathophysiological role for nicotinic receptors in schizophrenia. Activation by nicotine alters physiological dysfunctions, such as eye movement and sensory gating abnormalities, but effects on neuropsychological performance are just beginning to be investigated. Nicotine-induced desensitization and the well-known tachyphylaxis of nicotinic receptors may confound such efforts. In all, 20 schizophrenics, 10 smokers, and 10 nonsmokers were assessed following the administration of nicotine gum and placebo gum. The Repeatable Battery for the Assessment of Neuropsychological Status was administered. Nicotine affected only the Attention Index; there were no effects on learning and memory, language, or visuospatial/constructional abilities. Attentional function was increased in nonsmokers, but decreased in nicotine-abstinent smokers after nicotine administration. The effects of nicotine in schizophrenia do not extend to all areas of cognition. Effects on attention may be severely limited by tachyphylaxis, such that decremented performance occurs in smokers, while modest effects may be achieved in nonsmokers.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Adler LE, Hoffer LD, Wiser A, Freedman R (1993). Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150: 1856–1861.
Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R (1992). Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 32: 607–616.
Bates T, Pellett O, Stough C, Mangan G (1994). Effects of smoking on simple and choice reaction time. Psychopharmacology 114: 365–368.
Braff DL, Heaton R, Kuck J, Cullum M, Moranville J, Grant I et al (1991). The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry 48: 891–898.
Centers for Disease Control and Prevention (2003). Number (in millions) of adults 18 years and older who were current, former, or never smokers, overall and by sex, race, Hispanic origin, age, and education, National Health Interview Surveys, selected years—United States, 1965–2000. http://www.cdc.gov/tobacco/specpop.htm.
Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N et al (1999). Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73: 1590–1597.
Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH (1999). Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 21: 195–202.
First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders—Patient edition, (SCID-I/P, version 2.0). Biometrics Research Department, New York State Psychiatric Institute: New York.
Foulds J, Stapleton JA, Bell N, Swettenham J, Jarvis MJ, Russell MAH (1997). Mood and physiological effects of subcutaneous nicotine in smokers and never-smokers. Drug Alcohol Depen 44: 105–115.
Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94: 587–592.
Freedman R, Hall M, Adler LE, Leonard S (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22–33.
George TP, Sernyak MJ, Ziedonis DM, Woods SW (1995). Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 56: 344–346.
George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT et al (2002). Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26: 75–85.
Gilbert DG, Estes SL, Welser R (1997). Does noise stress modulate effects of smoking/nicotine? Mood, vigilance, and EEG responses. Psychopharmacology 129: 382–389.
Glassman AH (1993). Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150: 546–553.
Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE et al (1990). Smoking, smoking cessation, and major depression. JAMA 264: 1546–1549.
Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR (1997). Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 54: 159–165.
Greeman M, McClellan TA (1991). Negative effects of a smoking ban on an inpatient psychiatry service. Hosp Comm Psychiatry 42: 408–412.
Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321–330.
Green MF, Braff D (2001). Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry 49: 374–384.
Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R (1998). Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 44: 98–106.
Guan ZZ, Zhang X, Blennow K, Nordberg A (1999). Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 10: 1779–1782.
Harris JG, Adler LE, Young DA, Cullum CM, Rilling LM, Cicerello A et al (1996). Neuropsychological dysfunction in parents of schizophrenics. Schizophr Res 20: 253–260.
Hasenfratz M, Michel C, Nil R, Bättig K (1989). Can smoking increase attention in rapid information processing during noise? Electrocortical, physiological and behavioral effects. Psychopharmacology 98: 75–80.
Hatsukami DK, Fletcher L, Morgan S, Keenan R, Amble P (1989). The effects of varying cigarette deprivation duration on cognitive and performance tasks. J Subst Abuse 1: 407–416.
Heishman SJ, Taylor RC, Henningfield JE (1994). Nicotine and smoking: a rewiew of effects on human performance. Experimental and Clinical Psychopharmacology 2: 345–395.
Hindmarch I, Kerr JS, Sherwood N (1990). Effects of nicotine gum on psychomotor performance in smokers and non-smokers. Psychopharmacology 100: 535–541.
Kerr JS, Sherwood N, Hindmarch I (1991). Separate and combined effects of the social drugs on psychomotor performance. Psychopharmacology 104: 113–119.
Leonard S, Adler LE, Banhammou K, Berger R, Breese CR, Drebing C et al (2001). Smoking and mental illness. Pharmacol Biochem Behav 70: 561–570.
Levin ED, Wilson W, Rose J, McEvoy J (1996). Nicotine–haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15: 429–436.
Mancuso G, Lejeune M, Ansseau M (2001). Cigarette smoking and attention: processing speed or specific effects? Psychopharmacology 155: 372–378.
Mancuso G, Warburton DM, Melen M, Sherwood N, Tirelli E (1999). Selective effects of nicotine on attentional processes. Psychopharmacology 146: 199–204.
Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R et al (2001). Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22: 115–126.
McEvoy JP, Freudenreich O, Levin ED, Rose JE (1995). Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 119: 124–126.
McEvoy JP, Freudenreich O, Wilson WH (1999). Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 46: 125–129.
Meltzer HY (1992). Dimensions of outcome with clozapine. Br J Psychiatry 160: 46–53.
Michel C, Nil R, Buzzi R, Woodson PP, Battig K (1987). Rapid information processing and concomitant event-related brain potentials in smokers differing in CO absorption. Neuropsychobiology 17: 161–168.
Muir JL, Everitt BJ, Robbins TW (1994). AMPA-induced excitotoxic lesions of basal forebrain: A significant role for the cortical cholingeric system in attentional function. J Neurosci 14: 2313–2326.
National Institute on Drug Abuse (2001). Research Report Series—Nicotine Addiction, (On line). Available internet: www.drugabuse.gov/ResearchReports/Nicotine/nicotine3.html.
Nurnberger Jr JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al (1994). Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetic Initiative. Arch Gen Psychiatry 51: 849–859; (discussion 863–864).
Olincy A, Ross RG, Young DA, Roath M, Freedman R (1998). Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 18: 175–185.
Parrott AC, Craig D (1992). Cigarette smoking and nicotine gum (0, 2 and 4 mg): effects upon four visual attention tasks. Neuropsychobiology 25: 34–43.
Paulsen JS, Heaton RK, Sadek JR, Perry W, Delis DC, Braff D et al (1994). The nature of learning and memory impairments in schizophrenia. J Int Neuropsychol Soc 1: 88–99.
Petrie R, Deary T (1989). Smoking and human information processing. Psychopharmacology 99: 393–396.
Pritchard WS, Robinson JH, Guy TD (1992). Enhancement of continuous performance task reaction time by smoking in non-deprived smokers. Psychopharmacology 108: 437–442.
Provost SC, Woodward R (1991). Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology 104: 536–540.
Randolph C (1998). Repeatable Battery for the Assessment of Neuropsychological Status. The Psychological Corporation: San Antonio.
Revell AD (1988). Smoking and performance: a puff-by-puff analysis. Psychopharmacology 96: 563–565.
SAS Institute Inc (1999). SAS/STAT© User's Guide, Version 8. SAS Institute: Cary, NC. 3884pp.
Sherwood N, Kerr JS, Hindmarch I (1992). Psychomotor performance in smokers following single and repeated doses of nicotine gum. Special issue: nicotine. Psychopharmacology 108: 432–436.
Smith DA, Hoffman AF, David DJ, Adams CE, Gerhardt GA (1996). Nicotine-evoked nitric oxide release in the rat hippocampal slice. Neurosci Lett 255: 127–130.
Smith RC, Singh A, Infante M, Khandat A, Kloos A (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27: 479–497.
Snyder PR, Davis FC, Henningfield JE (1989). The tobacco withdrawal syndrome: Performance decrements assessed on a computerized test battery. Drug Alcohol Depend 23: 259–266.
Stevens K, Kem WR, Mahnir VM, Freedman R (1998). Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136: 320–327.
Tregellas JR, Tanabe JL, Martin LF, Freedman R (2004). fMRI of response to nicotine during a smooth pursuit eye movement task in schizophrenia (under review).
US Dept. of Health and Human Services (1988). The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General, US Department of Heal and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA 383–413.
Velasco J, Eells TD, Anderson R, Head M, Ryabik B, Mount R et al (1996). A two-year follow-up on the effects of a smoking ban in an inpatient psychiatric service. Psychiatric Serv 47: 869–871.
Voytko ML, Olton DS, Richardson RT, Gorman LK, Tobin JT, Price DL (1994). Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 14: 167–186.
Warburton DM (1990). Pharmacological aspects of nicotine. In Wonnacott S, Russell MAH, Stolerman IP (eds). Nicotine Psychopharmacology: Molecular, Cellular and Behavioural Aspects. Oxford University Press: Oxford.
Warburton DM, Arnall C (1994). Improvements in performance without nicotine withdrawal. Psychopharmacology 115: 539–542.
Wesnes K, Warburton DM (1978). The effects of cigarette smoking and nicotine tablets upon human attention. In Thornton RE (ed). Smoking Behaviour: Physiological and Psychological Influences. Churchill-Livingstone: London. pp 131–147.
Wesnes K, Warburton DM (1983). Smoking, nicotine and human performance. Pharmacol Ther 21: 189–208.
West R (1993). Beneficial effect of nicotine: fact or fiction? (Editorial). Addiction 88: 589–590.
Wilk CM, Gold JM, Bartko JJ, Dickerson F, Fenton WS, Knable M et al (2002). Test–retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry 159: 838–844.
Acknowledgements
This work was supported by USPHS Grants 1RO1 MH59109, 1RO1 MH61412.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harris, J., Kongs, S., Allensworth, D. et al. Effects of Nicotine on Cognitive Deficits in Schizophrenia. Neuropsychopharmacol 29, 1378–1385 (2004). https://doi.org/10.1038/sj.npp.1300450
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300450
Keywords
This article is cited by
-
Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation
Neuropsychopharmacology (2018)
-
Nicotine-induced activation of caudate and anterior cingulate cortex in response to errors in schizophrenia
Psychopharmacology (2018)
-
The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study
Neuropsychopharmacology (2016)
-
Brief Report: Initial Trial of Alpha7-Nicotinic Receptor Stimulation in Two Adult Patients with Autism Spectrum Disorder
Journal of Autism and Developmental Disorders (2016)
-
G72 primate-specific gene: a still enigmatic element in psychiatric disorders
Cellular and Molecular Life Sciences (2016)
